Home Biosciences is a biotech company dedicated to unlocking scientific breakthroughs by leveraging an asset-centric operating model. They are focused on generating precision medicines by leveraging the power of single-cell technologies.

A new breed of biotech company aiming to unlock scientific breakthrough by leveraging an asset-centric operating model

Redmile Group

Sofinnova Partners

Home Biosciences

Today, we are extremely happy to announce the creation of our first venture, One Biosciences. Focused on generating precision medicines by leveraging the power of single-cell technologies, One Biosciences is backed and supported by Institut Curie and co-founded by Dr. Céline Vallot, a pioneer of single-cell data analysis globally. It is our first venture of a portfolio of high-potential and well-designed transformative technologies and assets that we will bring to key value inflexion points in an expedited and capital efficient manner, by leveraging strong operational guidance and drug development expertise as well as funding resources under one roof.
David Schilansky Magali RICHARD 
➡️ https://lnkd.in/e7T3J3h
➡️ https://lnkd.in/ehxN8Ma
#homebiosciences #institutcurie #biotech #medicalresearch #science

Very happy to be featured as one of the groundbreaking medical start-ups in Paris, Ile-de-France for 2024.

#innovation #biotech #france2030 

https://lnkd.in/dnWBSEb5

Interesting read on biotech funding !  


Thank you Willow Shah-Neville and Labiotech.eu for quoting us in your article !

https://lnkd.in/eV3mmKCY

Merci au magazine Pharmaceutiques pour ce très bel article sur l'écosystème de la valorisation de l'innovation et de la recherche en santé. 

Home Biosciences, première société de biotechnologie dédiée au venture building en Europe Continentale est fière de s'inscrire dans cette démarche capitale pour l'innovation en France !

Merci à Juliette Badina✏️et Julie Wierzbicki pour le temps consacré à Home Biosciences dans la rédaction de cet article très riche.

Merci à nos actionnaires pour leur soutien constant qui s'inscrit pleinement dans le plan France2030eu:
Redmile Group, Sofinnova Partners

Merci à notre équipe qui permet de transformer ces brillantes innovations en solutions concrètes et nouvelles thérapies pour les patients 
Nicolas Doulet, Guillaume Hagege, ROMAIN LETOURNEUR, Magali RICHARD, David Schilansky, Reine Wang

https://lnkd.in/eBP2h-e


COM:HOMEBIOSCIENCES

Home Biosciences

Analysis Not Available